Nature’s Toolbox (NTx), a life sciences company developing next-gen platforms for RNA and protein manufacturing, announced the full commercial availability of NTxscribe, a benchtop, continuous flow RNA in vitro transcription (IVT) and purification system for scalable RNA manufacturing.

NTxscribe aims to address the challenges of costly and complex traditional RNA production methods, with a benchtop system that produces high-yield, high-integrity RNA in continuous flow that can scale from small research doses to commercial volumes. NTxscribe produces 10-50 mg of high integrity RNA in two hours, shortening timelines.

NTxscribe’s small footprint enables rapid deployment even in mobile cleanrooms. Lower infrastructure costs make high-quality RNA production accessible to a wider range of organizations, including smaller labs and startups. NTxscribe also utilizes 100% U.S. made raw materials and enables an end-to-end domestic supply chain for critical biomaterials.

“Traditional biomanufacturing methods have not been able to keep pace with the surge in therapeutic innovation and rise of personalized medicine, and until now, there has not been a solution for the gaps in scalability and quality,” said Jamie Coffin, President and CEO at NTx. “Following our fully subscribed early access program with leading academic medical centers and major biopharma organizations, we are excited to bring NTxscribe to the broader market and help unlock the full potential of RNA therapies by enabling innovation for the future of medicine.”